For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

Resources

Renal Cell Carcinoma

Cabometyx® (Cabozantinib) therapeutic indications

Cabometyx® is indicated as monotherapy treatment of advanced renal cell carcinoma (RCC):

  • in first-line treatment of adult patients with intermediate or poor risk per IMDC criteria.
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx® in combination with nivolumab for the first-line treatment of RCC in adults.

Support for Your Patients

Nutrition and Cancer
Nutrition and Cancer

Available resources and nutritional advise for patients experiencing malnutrition, weight or muscle loss.

CMX-IE-000765 | September 2025
What to Expect with Cabometyx<sup>®</sup>
What to Expect with Cabometyx®
Video 5:48

This video highlights some of the common side effects that may be experienced with Cabometyx®, including advice on how best to manage them.

CMX-IE-000760 | August 2025
Understanding Kidney Cancer and Your Treatment
Understanding Kidney Cancer and Your Treatment
Video 5:23

This video provides an introduction to kidney cancer and gives an overview of treatment with Cabometyx®.

CMX-IE-000759 | August 2025
A Patient’s Guide to Cabometyx<sup>®</sup>
A Patient’s Guide to Cabometyx®
PDF / PowerPoint Deck 68 pages

This booklet is designed to support patients taking Cabometyx®. It contains information about dosing and side effects, including tips for managing them.

CMX-IE-000757 | August 2025

2L Data

Managing Adverse Events for Cabometyx<sup>®</sup> Monotherapy
Managing Adverse Events for Cabometyx® Monotherapy
PDF / PowerPoint Deck 18 pages

This booklet is designed to aid the effective management of adverse events in your patients.

CMX-IE-000763 | August 2025
Take Control of aRCC in Second-line with Cabometyx<sup>®</sup>
Take Control of aRCC in Second-line with Cabometyx®
PDF / PowerPoint Deck 4 pages

This top-line summary provides the key information around using Cabometyx® in second-line treatment.

CMX-IE-000762 | August 2025
Efficacy information
Efficacy information

Efficacy Information from Meteor Study showing Overall Survival, PFS and ORR vs everolimus.

CMX-IE-000764 | September 2025

Contact your Ipsen representative

Send request
Resources

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

To access relevant information about Renal Cell Carcinoma, please choose one of the following options:

I am a healthcare professional in Ireland

This section is for healthcare professionals only. Contains promotional information

I am a healthcare professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Cabometyx® (cabozantinib) in Ireland. It is designed for patients in Ireland and should not replace the opinion provided by your healthcare professional or the details contained in the Patient Information Leaflet.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.